Table 1

Detailed demographics and clinical characteristics of the patients in both groups that were examined in this study

ParameterpSpA (n=30)non-SpA (n=30)P value
Male gender (%)53.320.00.008
Age (years, mean±SD)37.5±5.936.9±7.70.694
CRP (mg/dL) mean±SD0.54±0.90.58±0.90.473
ESR (mm/1 hour, mean±SD)15.2±18.414.9±11.50.486
HLA-B27 positive (%)66.7%13.3%0.001
Symptom duration (months)17.2±27.54.4±4.30.005
PatGA (0–10, mean±SD)5.6±1.66.5±2.50.066
PhysGA (0–10, mean±SD)5.2±1.46.1±2.20.099
BASDAI (0–10, mean±SD)5.3±2.9
ASDAS (mean±SD)2.1±ß.7
BASFI (0–10, mean±SD)4.7±2.3
ASQoL (mean±SD)9.9±5.2
NSAIDs intake (% patients)66.756.70.430
NSAID index (mean±SD)37.0±42.222.4±30.60.161
Steroids intake (% patients)23.326.70.767
DMARDs intake (% patients)16.733.30.139
Biologics intake (% patients)
  • ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life Questionnaire; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; non-SpA, other diagnoses than spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PatGA, patients’ global assessment; PhysGA, physicians’ global assessment; pSpA, peripheral spondyloarthritis.